Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $87.88 USD
Change Today +0.03 / 0.03%
Volume 880.9K
HSP On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

hospira inc (HSP) Snapshot

Open
$87.89
Previous Close
$87.85
Day High
$87.94
Day Low
$87.76
52 Week High
03/24/15 - $88.09
52 Week Low
04/11/14 - $42.01
Market Cap
15.1B
Average Volume 10 Days
1.8M
EPS TTM
$2.17
Shares Outstanding
172.4M
EX-Date
--
P/E TM
40.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for HOSPIRA INC (HSP)

hospira inc (HSP) Details

Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprise Biosimilars that include Retacrit, an EPO, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent; and Inflectra, a biosimilar infliximab for the treatment of patients with autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease. In addition, it offers medication management products, including infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, the company provides intravenous solutions and nutritional products; and contract manufacturing services, as well as develops proprietary pharmaceutical products, such as Dyloject, a nonsteroidal anti-inflammatory drug analgesic. It serves hospitals and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company has collaborative arrangements with Bioceuticals Arzneimittel AG to license and market Retacrit; and Q Core Medical, Ltd to market and distribute Sapphire, a multi-therapy infusion system. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.

19,000 Employees
Last Reported Date: 02/12/15
Founded in 2003

hospira inc (HSP) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $477.4K
Senior Vice President of Operations
Total Annual Compensation: $464.7K
President of Hospira Medical Devices
Total Annual Compensation: $512.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $550.5K
Compensation as of Fiscal Year 2014.

hospira inc (HSP) Key Developments

Clinigen Group Plc Extends Foscavir U.S Distribution Contract with Hospira, Inc

Clinigen Group Plc announced the extension and renegotiation of the exclusive license and distribution agreement with Hospira Inc. for its anti-viral product Foscavir (foscarnet sodium) in the U.S. This is expected to be beneficial to both parties. The original distribution agreement with Hospira established in July 2011 was due to expire in May 2017. The new agreement is for five years extending the term to 31 December 2019.

Hospira Launches Remicade Biosimilar Inflectra in Additional European Countries

Hospira announced that it is launching its Remicade biosimilar Inflectra in at least 10 new European markets, nearly doubling the product's presence on the continent. Inflectra (infliximab) is the first biosimilar monoclonal antibody to be marketed in Europe, will soon be available in Austria, Sweden, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands and Spain. Inflectra mimics Janssen's Remicade (infliximab), which treats inflammatory diseases such as psoriatic and rheumatoid arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, plaque psoriasis and ulcerative colitis.

Hospira Posts Interim Results from Patient Registry for Biosimilar Inflectra in IBD Treatment

Hospira (US) presented interim results from a patient registry study at the European Crohn's and Colitis Organisation's conference on inflammatory bowel diseases (IBDs) in Barcelona, Spain, on 19 February. The study looked at the firm's biosimilar version of Remicade (infliximab; Johnson & Johnson; J&J, US), Inflectra. The results from the ongoing independent, prospective study conducted in 90 patients across Hungary demonstrated comparable efficacy between Inflectra and Remicade for inducing and maintaining remission of Crohn's disease (CD) and ulcerative colitis (UC). So far, the patients who were treated with Inflectra for either CD (57) or UC (33) demonstrated reductions in disease activity at two and six weeks post treatment. Levels of C-reactive protein, a marker for inflammation, also declined in UC patients. With regards to safety and tolerability, Hospira reports that 4 of the 90 patients had an allergic reaction to Inflectra. The four patients have previously received anti- tumour necrosis factor treatment. The registry trial will continue to enrol patients and will follow CD patients for 108 weeks and UC patients for 54 weeks in order to assess the safety, adherence, long-term outcomes, and the cost of treatment with Inflectra.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSP:US $87.88 USD +0.03

HSP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chugai Pharmaceutical Co Ltd ¥3,855 JPY -10.00
Cintas Corp $82.38 USD +1.25
Mallinckrodt PLC $129.61 USD +2.83
UCB SA €68.49 EUR +0.87
Zimmer Holdings Inc $117.50 USD +1.85
View Industry Companies
 

Industry Analysis

HSP

Industry Average

Valuation HSP Industry Range
Price/Earnings 45.0x
Price/Sales 3.3x
Price/Book 4.5x
Price/Cash Flow 45.5x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HOSPIRA INC, please visit www.hospira.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.